# Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

- Link: https://www.thailand-business-news.com/pr-news/everest-medicines-announces-close-of-exclusive-licensing-agreement-with-travere-therapeutics-for-civorebrutinib
- Published: 2026-07-07T17:53:00+07:00
- Author: PR Newswire

SHANGHAI, July 7, 2026 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, "Everest",
or the "Company"), a biopharmaceutical company focused on the discovery, clinical
development, manufacturing, and commercialization of innovative therapeutics, today
announced the closing of its previously announced exclusive licensing and collaboration
agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and
commercialization of civorebrutinib (also known as EVER001), a potential best-in-
class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in the 
U.S. and global markets excluding Greater China and certain countries in East and
Southeast Asia.

Under the terms of the agreement, Everest will receive an upfront payment of $112.5
million from Travere Therapeutics after the closing of the transaction. Everest 
is also eligible to receive up to approximately $1.03 billion in additional cash
payments tied to specified clinical development, regulatory and commercial milestones
across up to five indications. Travere will also pay tiered royalties on future 
sales in its licensed territories, ranging from high single-digit to double-digit
percentages based on annual net sales thresholds.

**About Civorebrutinib **

Civorebrutinib (also known as EVER001) is a next-generation covalent reversible 
Bruton’s tyrosine kinase (BTK) inhibitor in development globally for the treatment
of renal diseases. BTK is an essential component of the B-cell receptor signaling
pathways that regulate the survival, activation, proliferation, and differentiation
of B lymphocytes. Targeting BTK with small molecule inhibitors has been demonstrated
to be an effective treatment option for B-cell autoimmune diseases.

**About Everest Medicines**

Everest Medicines is a biopharmaceutical company focused on discovering, developing,
manufacturing and commercializing innovative pharmaceutical products that address
critical unmet medical needs for patients in global markets. The management team
of Everest Medicines has deep expertise and an extensive track record both in China
and with leading global pharmaceutical companies.

The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical
care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines
has developed a fully integrated commercialization platform that combines omnichannel
commercial capabilities with end-to-end product lifecycle management. Leveraging
its proprietary mRNA platform, the Company is advancing its existing pipeline, including
mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional
high-value therapeutic areas with blockbuster potential, and accelerating its global
expansion. For more information, please visit the Company’s website: [**www.everestmedicines.com**](http://www.everestmedicines.com/).

**About Travere Therapeutics**

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company
that comes together every day to help patients, families and caregivers of all backgrounds
as they navigate life with a rare disease. On this path, we know the need for treatment
options is urgent – that is why our global team works with the rare disease community
to identify, develop and deliver life-changing therapies. In pursuit of this mission,
we continuously seek to understand the diverse perspectives of rare patients and
to courageously forge new paths to make a difference in their lives and provide 
hope – today and tomorrow. For more information, visit [travere.com](http://travere.com/).

**Forward-Looking Statements**

This news release may make statements that constitute forward-looking statements,
including descriptions regarding the intent, belief or current expectations of the
Company or its officers with respect to the business operations and financial condition
of the Company, which can be identified by terminology such as "will," "expects","
anticipates", "future", "intends", "plans", "believes", "estimates", "confident"
and similar statements. Such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, or other factors, some of which
are beyond the control of the Company and are unforeseeable. Therefore, the actual
results may differ from those in the forward-looking statements as a result of various
factors and assumptions, such as future changes and developments in our business,
competitive environment, political, economic, legal and social conditions. The Company
or any of its affiliates, directors, officers, advisors or representatives has no
obligation and does not undertake to revise forward-looking statements to reflect
new information, future events or circumstances after the date of this news release,
except as required by law.

_This press release is available in both Chinese and English. In the event of any
inconsistency, ambiguity or discrepancy between the two versions, the English version
shall prevail. The Company shall not be liable for any misunderstanding arising 
from translation or interpretation differences._

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib ](http://www.prnasia.com/story/archive/4999306_AE99306_0?rand=184833)